Study Evaluating Prevenar in High-Risk Children

NCT00234338

Last updated date
Study Location
Frankfurt, , 60590, Germany
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Pneumococcal Disease
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
2-5 years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- High-risk children ages 2 to 5 years old

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Prior administration of Prevenar


- Prior and/or concurrent administration of 23 vPs vaccine

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Pneumococcal DiseaseSafety and Immunogenicity Study of 20vPnC in Healthy Children 15 Months Through 17 Years of Age
NCT04642079
  1. Chamblee, Georgia
  2. Sioux City, Iowa
  3. Binghamton, New York
  4. Dayton, Ohio
  5. Austin, Texas
  6. San Antonio, Texas
  7. Murray, Utah
  8. Provo, Utah
  9. Salt Lake City, Utah
  10. Salt Lake City, Utah
  11. Salt Lake City, Utah
  12. South Jordan, Utah
  13. Syracuse, Utah
  14. Charlottesville, Virginia
  15. Charlottesville, Virginia
  16. Charlottesville, Virginia
ALL GENDERS
15 Months+
years
MULTIPLE SITES
Pneumococcal Disease20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 3-Dose Series in Healthy Infants
NCT04546425
  1. Milano, Milan
  2. Firenze,
  3. Foggia,
  4. Haarlem,
  5. Hoofddorp,
  6. Oslo,
  7. Westmead, New South Wales
  8. Nedlands, Western Australia
  9. Nedlands, Western Australia
  10. Brussels,
  11. Edegem,
  12. Jindrichuv Hradec,
  13. Jindrichuv Hradec,
  14. Jindrichuv Hradec,
  15. Pardubice,
  16. Praha 3,
  17. Praha 6,
  18. Sezemice,
  19. Tallinn,
  20. Tallinn,
  21. Tallinn,
  22. Tallinn,
  23. Tartu,
  24. Espoo,
  25. Helsinki,
  26. Helsinki,
  27. Järvenpää,
  28. Kokkola,
  29. Oulu,
  30. Pori,
  31. Seinajoki,
  32. Tampere,
  33. Turku,
  34. Bydgoszcz,
  35. Bydgoszcz,
  36. Debica,
  37. Krakow,
  38. Krakow,
  39. Leczna,
  40. Lodz,
  41. Lubon,
  42. Siemianowice Slaskie,
  43. Torun,
  44. Trzebnica,
  45. Warszawa,
  46. Warszawa,
  47. Wroclaw,
  48. Wroclaw,
  49. Bratislava,
  50. Bratislava,
  51. Detva,
  52. Horne Srnie,
  53. Humenne,
  54. Humenné,
  55. Kosice,
  56. Liptovská Osada,
ALL GENDERS
42 Days+
years
MULTIPLE SITES
Pneumococcal Disease20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study in Healthy Japanese Infants
NCT04530838
  1. Isumi-city, Chiba
  2. Fukuoka-city, Fukuoka
  3. Fukuoka-shi, Fukuoka
  4. Osaka-City, Osaka
  5. Ritto-Shi, Shiga
  6. Nagoya-shi, Aichi
  7. Toyota-shi, Aichi
  8. Chiba-shi, Chiba
  9. Funabashi-city, Chiba
  10. Yotsukaido-shi, Chiba
  11. Yotsukaido-shi, Chiba
  12. Fukui-shi, Fukui
  13. Fukuoka-City, Fukuoka
  14. Fukuoka-city, Fukuoka
  15. Iizuka, Fukuoka
  16. Kasuga-city, Fukuoka
  17. Gifu-city, Gifu
  18. Ebetsu Shi, Hokkaido
  19. Sapporo shi, Hokkaido
  20. Sapporo, Hokkaido
  21. Akashi-City, Hyōgo
  22. Kawasaki-shi, Kanagawa
  23. Kumamoto Shi, Kumamoto
  24. Kumamoto-shi, Kumamoto
  25. Kuwana-city, MIE
  26. Nagano-shi, Nagano
  27. Kawachinagano, Osaka
  28. Ureshino-shi, Saga
  29. Hanyu-shi, Saitama
  30. Kumagaya-shi, Saitama
  31. Fuchu-city, Tokyo
  32. Nishitokyo-shi, Tokyo
  33. Setagaya-ku, Tokyo
  34. Setagaya-ku, Tokyo
  35. Shinjuku-ku, Tokyo
  36. Suginami-ku, Tokyo
  37. Kofu-city, Yamanashi
  38. Tsuru-shi, Yamanashi
ALL GENDERS
2 Months+
years
MULTIPLE SITES
Pneumococcal DiseaseSafety and Immunogenicity of 20vPnC Coadministered With SIIV in Adults ≥65 Years of Age
NCT04526574
  1. Miami Lakes, Florida
  2. Miami, Florida
  3. Wilmington, North Carolina
  4. Oklahoma City, Oklahoma
  5. Wauwatosa, Wisconsin
  6. Birmingham, Alabama
  7. Mobile, Alabama
  8. Chandler, Arizona
  9. Phoenix, Arizona
  10. Tempe, Arizona
  11. Redding, California
  12. San Diego, California
  13. San Diego, California
  14. Walnut Creek, California
  15. Coral Gables, Florida
  16. Crystal River, Florida
  17. Hialeah, Florida
  18. Jacksonville, Florida
  19. Miami, Florida
  20. Orlando, Florida
  21. Orlando, Florida
  22. Savannah, Georgia
  23. Stockbridge, Georgia
  24. Meridian, Idaho
  25. El Dorado, Kansas
  26. Wichita, Kansas
  27. Wichita, Kansas
  28. Metairie, Louisiana
  29. New Orleans, Louisiana
  30. Elkridge, Maryland
  31. Rockville, Maryland
  32. Saint Louis, Missouri
  33. Norfolk, Nebraska
  34. Omaha, Nebraska
  35. Las Vegas, Nevada
  36. Las Vegas, Nevada
  37. Binghamton, New York
  38. Endwell, New York
  39. Charlotte, North Carolina
  40. Greensboro, North Carolina
  41. Hickory, North Carolina
  42. Raleigh, North Carolina
  43. Raleigh, North Carolina
  44. Rocky Mount, North Carolina
  45. Rocky Mount, North Carolina
  46. Fargo, North Dakota
  47. Cincinnati, Ohio
  48. Cincinnati, Ohio
  49. Cleveland, Ohio
  50. Franklin, Ohio
  51. Warwick, Rhode Island
  52. Little River, South Carolina
  53. Mount Pleasant, South Carolina
  54. Bristol, Tennessee
  55. Nashville, Tennessee
  56. Austin, Texas
  57. Cedar Park, Texas
  58. Fort Worth, Texas
  59. Fort Worth, Texas
  60. Houston, Texas
  61. McKinney, Texas
  62. Pearland, Texas
  63. San Antonio, Texas
  64. Tomball, Texas
  65. Tomball, Texas
  66. Draper, Utah
  67. Salt Lake City, Utah
  68. Salt Lake City, Utah
  69. South Jordan, Utah
  70. Norfolk, Virginia
  71. Richmond, Virginia
ALL GENDERS
65 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title Study Evaluating Prevenar in High-Risk Children
Official Title Prospective Post-Marketing Surveillance Study of Prevenar in High-Risk Children Aged 2 to 5 Years
Brief Summary The purpose of this study is to estimate the local and systemic tolerability of Prevenar in children ages 2 to 5 years old in usual care settings.
Detailed Description Not Provided
Study Type Observational
Study Design Time Perspective: Prospective
Target Follow-Up Duration Not Provided
Biospecimen Not Provided
Sampling Method Not Provided
Study Population Not Provided
Condition Pneumococcal Disease
Intervention Not Provided
Study Groups/Cohorts Not Provided
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Completed
Estimated Enrollment
 (submitted: October 5, 2005)
5000
Original Enrollment Same as current
Actual Study Completion Date April 2007
Primary Completion Date Not Provided
Eligibility Criteria

Inclusion Criteria:

  • High-risk children ages 2 to 5 years old

Exclusion criteria:

  • Prior administration of Prevenar
  • Prior and/or concurrent administration of 23 vPs vaccine
Sex/Gender
Sexes Eligible for Study:All
Ages 2 Years to 5 Years   (Child)
Accepts Healthy Volunteers Yes
Contacts Contact information is only displayed when the study is recruiting subjects
Listed Location Countries Germany
Removed Location Countries  
 
Administrative Information
NCT Number NCT00234338
Other Study ID Numbers 101850
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement Not Provided
Responsible Party Not Provided
Study Sponsor Wyeth is now a wholly owned subsidiary of Pfizer
Collaborators Not Provided
Investigators
Study Director:Medical MonitorWyeth is now a wholly owned subsidiary of Pfizer
Principal Investigator:Trial ManagerFor Germany, [email protected]
PRS Account Wyeth is now a wholly owned subsidiary of Pfizer
Verification Date December 2007